# Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

> **NCT04704869** · PHASE3 · COMPLETED · sponsor: **Bryan Cotton** · enrollment: 1604 (actual)

## Conditions studied

- Trauma Injury

## Interventions

- **BIOLOGICAL:** Cryoprecipitate
- **BIOLOGICAL:** Red Blood Cells
- **BIOLOGICAL:** Plasma
- **BIOLOGICAL:** Platelets
- **BIOLOGICAL:** Whole Blood

## Key facts

- **NCT ID:** NCT04704869
- **Lead sponsor:** Bryan Cotton
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 1604 (ACTUAL)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704869, "Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04704869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*